Sorafenib, also known as BAY 43-9006, is a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Sorafenib was approved in 2005 for use in the treatment of advanced renal cancer.
MedKoo Cat#: 100770
Name: Sorafenib free base
CAS#: 284461-73-0 (free base)
Chemical Formula: C21H16ClF3N4O3
Exact Mass: 464.0863
Molecular Weight: 464.82
Elemental Analysis: C, 54.26; H, 3.47; Cl, 7.63; F, 12.26; N, 12.05; O, 10.33
| Solvent | mg/mL | mM | comments | |
|---|---|---|---|---|
| Solubility | ||||
| DMSO | 41.6 | 89.45 | ||
| DMSO:PBS (pH 7.2) (1:2) | 0.3 | 0.65 | ||
| DMF | 20.0 | 43.03 |
The following data is based on the product molecular weight 464.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
